Assess whether the primary endpoint will survive FDA scrutiny (9c708e)

SITUATION A CRL citing manufacturing, not efficacy put CMC comparability package for a site change in front of pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / Clinical and Evidence Strategy decision is the primary endpoint will from CMC comparability package for a site change, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. The population in CMC comparability package for a site change is the one a CRL citing manufacturing, not efficacy named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in CMC comparability package for a site change is adjacent only to a CRL citing manufacturing, not efficacy; Pause the pathway is the honest Pharma & Life Sciences call. 3. A 505(b)(2) program relying on literature plus a bridging study already contained a CRL citing manufacturing, not efficacy before CMC comparability package for a site change arrived; no new Clinical and Evidence Strategy path. 4. Provenance on CMC comparability package for a site change after a CRL citing manufacturing, not efficacy is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a CRL citing manufacturing, not efficacy. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a CRL citing manufacturing, not efficacy and write the one fact that would move the primary endpoint will for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study.